Liu Yong, Chen Li, Peng Shuyou, Chen Zhouxun, Gimm Oliver, Finke Rainer, Hoang-Vu Cuong
Department of Surgery, The Second Affiliated Hospital of Zhejiang University, Hangzhou, PR China.
Oncol Rep. 2005 Dec;14(6):1413-20.
CD97EGF is a member of the EGF-TM7 family of class II seven-transmembrane (7TM), and its cellular ligand CD55 (also known as decay accelerating factor; DAF) protects host cells from complement attack. To determine whether the expression levels of these two molecules are correlated with the clinicopathological features of gastric carcinomas, a total of 35 gastric carcinomas and their corresponding margins and normal specimens were investigated by RT-PCR, Western blot analysis and immunohistochemistry. Transcript levels of CD97EGFand CD55 were higher in tumors than those in the margin and normal epithelial mucous tissues (P<0.05). However, the expression levels of CD97EGF and CD55 mRNA had no correlation with the clinicopathological features of gastric carcinoma patients. All three groups of specimens were immunoreactive for CD97EGF and the CD55 protein. Strong and specific immunoreactivities of CD97EGF were located in the mucosal epithelia of the marginal basal membrane. Expression of CD97(EGF) in the margins showed a marked difference between the depth of tumor invasion T1 and T2, 3 and 4, and stages I and II/III/IV of gastric carcinomas (P<0.05). The expression of CD55 protein was highly correlated with CD97EGF (R=0.6483, P<0.001). Western blot analysis confirmed the expression and distribution patterns of CD97EGF and CD55. Our findings suggest that CD97EGF may play a role in the development and invasion of gastric carcinomas by binding its cellular ligand CD55. Detection of the CD97EGF expression in the tumor margin could be referred to as the molecular edge of gastric carcinomas.
CD97EGF是II类七跨膜（7TM）EGF-TM7家族的成员，其细胞配体CD55（也称为衰变加速因子；DAF）可保护宿主细胞免受补体攻击。为了确定这两种分子的表达水平是否与胃癌的临床病理特征相关，通过逆转录聚合酶链反应（RT-PCR）、蛋白质免疫印迹分析和免疫组织化学对35例胃癌及其相应切缘和正常标本进行了研究。CD97EGF和CD55的转录水平在肿瘤中高于切缘和正常上皮黏膜组织（P<0.05）。然而，CD97EGF和CD55 mRNA的表达水平与胃癌患者的临床病理特征无关。所有三组标本对CD97EGF和CD55蛋白均呈免疫反应性。CD97EGF的强而特异性免疫反应位于边缘基底膜的黏膜上皮。CD97(EGF)在切缘的表达在胃癌肿瘤浸润深度T1和T2、3和4以及I期和II/III/IV期之间存在显著差异（P<0.05）。CDSS蛋白的表达与CD97EGF高度相关（R=0.6483，P<0.001）。蛋白质免疫印迹分析证实了CD97EGF和CD55的表达及分布模式。我们的研究结果表明，CD97EGF可能通过结合其细胞配体CD55在胃癌的发生和侵袭中发挥作用。检测肿瘤切缘中CD97EGF的表达可作为胃癌的分子边界。
